Stock Watch: Why Have All The Buyouts Gone?
Due Diligence Tempers Pharma's Drive To Refresh Pipeline Through M&A
Clinical trial results that readily excite stock market investors are subject to more stringent analysis by big pharma deal-hunters, despite their urgent need for pipeline renewal.
